CN102292083A - 包括7-羟基-苯并咪唑-4-基-甲酮衍生物的糖原合酶激酶-3β抑制剂 - Google Patents
包括7-羟基-苯并咪唑-4-基-甲酮衍生物的糖原合酶激酶-3β抑制剂 Download PDFInfo
- Publication number
- CN102292083A CN102292083A CN2009801549899A CN200980154989A CN102292083A CN 102292083 A CN102292083 A CN 102292083A CN 2009801549899 A CN2009801549899 A CN 2009801549899A CN 200980154989 A CN200980154989 A CN 200980154989A CN 102292083 A CN102292083 A CN 102292083A
- Authority
- CN
- China
- Prior art keywords
- benzo
- hydroxy
- imidazoles
- methanamide
- thiophene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 *c1ccc(-c2nc(c(C(N[C@@]3CNCCC3)=O)ccc3O)c3[n]2)[s]1 Chemical compound *c1ccc(-c2nc(c(C(N[C@@]3CNCCC3)=O)ccc3O)c3[n]2)[s]1 0.000 description 2
- RUJOHZSWMBDDQW-CQSZACIVSA-N CC(C)(C)OC(N(CCC1)C[C@@H]1NC(c(c1c2[nH]c(-c3ccc[s]3)n1)ccc2OC)=O)=O Chemical compound CC(C)(C)OC(N(CCC1)C[C@@H]1NC(c(c1c2[nH]c(-c3ccc[s]3)n1)ccc2OC)=O)=O RUJOHZSWMBDDQW-CQSZACIVSA-N 0.000 description 1
- RUNHWGOJLZUOJS-SHTZXODSSA-N CC(C)(C)OC(N[C@H](CC1)CC[C@@H]1NC(c(c1c2[nH]c(-c3ccc[s]3)n1)ccc2OC)=O)=O Chemical compound CC(C)(C)OC(N[C@H](CC1)CC[C@@H]1NC(c(c1c2[nH]c(-c3ccc[s]3)n1)ccc2OC)=O)=O RUNHWGOJLZUOJS-SHTZXODSSA-N 0.000 description 1
- UMDBYBUACBGSNK-UHFFFAOYSA-N COC(c(cc1)cc(NC(c2ccc[s]2)=N)c1OC)=O Chemical compound COC(c(cc1)cc(NC(c2ccc[s]2)=N)c1OC)=O UMDBYBUACBGSNK-UHFFFAOYSA-N 0.000 description 1
- LJPSIRPRIUNDAT-UHFFFAOYSA-N Oc1ccc(C(NC2CNCCC2)=O)c2c1[nH]c(-c1ccc[s]1)n2 Chemical compound Oc1ccc(C(NC2CNCCC2)=O)c2c1[nH]c(-c1ccc[s]1)n2 LJPSIRPRIUNDAT-UHFFFAOYSA-N 0.000 description 1
- DLNUWZOWSGXCKJ-UHFFFAOYSA-N Oc1ccc(C(NCC2CCNCC2)=O)c2c1[nH]c(-c1ccc[s]1)n2 Chemical compound Oc1ccc(C(NCC2CCNCC2)=O)c2c1[nH]c(-c1ccc[s]1)n2 DLNUWZOWSGXCKJ-UHFFFAOYSA-N 0.000 description 1
- FOPKNXVYPWDCPH-UHFFFAOYSA-N Oc1ccc(C(NCC2CCNCC2)=O)c2c1[nH]c(C1CC1)n2 Chemical compound Oc1ccc(C(NCC2CCNCC2)=O)c2c1[nH]c(C1CC1)n2 FOPKNXVYPWDCPH-UHFFFAOYSA-N 0.000 description 1
- PQOKBQCVPUXWDC-UHFFFAOYSA-N Oc1ccc(C(NCC2CNCCC2)=O)c2c1[nH]c(C1C(CC3)CC3C1)n2 Chemical compound Oc1ccc(C(NCC2CNCCC2)=O)c2c1[nH]c(C1C(CC3)CC3C1)n2 PQOKBQCVPUXWDC-UHFFFAOYSA-N 0.000 description 1
- LJPSIRPRIUNDAT-SNVBAGLBSA-N Oc1ccc(C(N[C@H]2CNCCC2)=O)c2c1[nH]c(-c1ccc[s]1)n2 Chemical compound Oc1ccc(C(N[C@H]2CNCCC2)=O)c2c1[nH]c(-c1ccc[s]1)n2 LJPSIRPRIUNDAT-SNVBAGLBSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11654308P | 2008-11-20 | 2008-11-20 | |
| US61/116,543 | 2008-11-20 | ||
| PCT/JP2009/004975 WO2010058512A1 (en) | 2008-11-20 | 2009-09-29 | Glycogen synthase kinase-3 beta inhibitors containing 7-hydroxy-benzoimidazole-4-yl-methanone derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102292083A true CN102292083A (zh) | 2011-12-21 |
Family
ID=42197956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009801549899A Withdrawn CN102292083A (zh) | 2008-11-20 | 2009-09-29 | 包括7-羟基-苯并咪唑-4-基-甲酮衍生物的糖原合酶激酶-3β抑制剂 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20110301146A1 (enExample) |
| EP (1) | EP2358365A4 (enExample) |
| JP (1) | JP2012509249A (enExample) |
| KR (1) | KR20110086750A (enExample) |
| CN (1) | CN102292083A (enExample) |
| AU (1) | AU2009318719A1 (enExample) |
| BR (1) | BRPI0920959A2 (enExample) |
| CA (1) | CA2744012A1 (enExample) |
| CO (1) | CO6361935A2 (enExample) |
| IL (1) | IL212704A0 (enExample) |
| MX (1) | MX2011005369A (enExample) |
| RU (1) | RU2011124960A (enExample) |
| SG (1) | SG171761A1 (enExample) |
| WO (1) | WO2010058512A1 (enExample) |
| ZA (1) | ZA201104487B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010014794A1 (en) * | 2008-07-30 | 2010-02-04 | Oncotherapy Science, Inc. | Benzoimidazole derivatives and glycogen synthase kinase-3 beta inhibitors containing the same |
| CN101619058A (zh) * | 2009-01-08 | 2010-01-06 | 上海交通大学 | 一种苯并咪唑-4-酰胺型衍生物 |
| CN114072407A (zh) | 2019-04-02 | 2022-02-18 | 阿里戈斯治疗公司 | 靶向prmt5的化合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004065370A1 (en) * | 2003-01-23 | 2004-08-05 | Crystalgenomics, Inc. | Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof |
| TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| CA2741988A1 (en) * | 2008-10-30 | 2010-05-06 | Oncotherapy Science, Inc. | 7-hydroxy-benzoimidazole-4-yl-methanone derivatives and pbk inhibitors containing the same |
-
2009
- 2009-09-29 MX MX2011005369A patent/MX2011005369A/es unknown
- 2009-09-29 US US13/129,361 patent/US20110301146A1/en not_active Abandoned
- 2009-09-29 CA CA2744012A patent/CA2744012A1/en not_active Abandoned
- 2009-09-29 EP EP09827294A patent/EP2358365A4/en not_active Withdrawn
- 2009-09-29 RU RU2011124960/04A patent/RU2011124960A/ru unknown
- 2009-09-29 JP JP2011522179A patent/JP2012509249A/ja not_active Withdrawn
- 2009-09-29 WO PCT/JP2009/004975 patent/WO2010058512A1/en not_active Ceased
- 2009-09-29 SG SG2011036282A patent/SG171761A1/en unknown
- 2009-09-29 KR KR1020117014051A patent/KR20110086750A/ko not_active Withdrawn
- 2009-09-29 BR BRPI0920959A patent/BRPI0920959A2/pt not_active IP Right Cessation
- 2009-09-29 CN CN2009801549899A patent/CN102292083A/zh not_active Withdrawn
- 2009-09-29 AU AU2009318719A patent/AU2009318719A1/en not_active Withdrawn
-
2011
- 2011-05-05 IL IL212704A patent/IL212704A0/en unknown
- 2011-05-19 CO CO11061830A patent/CO6361935A2/es not_active Application Discontinuation
- 2011-06-17 ZA ZA2011/04487A patent/ZA201104487B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2011124960A (ru) | 2012-12-27 |
| JP2012509249A (ja) | 2012-04-19 |
| SG171761A1 (en) | 2011-07-28 |
| KR20110086750A (ko) | 2011-07-29 |
| BRPI0920959A2 (pt) | 2017-07-11 |
| CA2744012A1 (en) | 2010-05-27 |
| ZA201104487B (en) | 2012-03-28 |
| CO6361935A2 (es) | 2012-01-20 |
| IL212704A0 (en) | 2011-07-31 |
| MX2011005369A (es) | 2011-06-20 |
| US20110301146A1 (en) | 2011-12-08 |
| EP2358365A1 (en) | 2011-08-24 |
| WO2010058512A1 (en) | 2010-05-27 |
| AU2009318719A1 (en) | 2011-06-30 |
| EP2358365A4 (en) | 2012-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102271514A (zh) | 7-羟基-苯并咪唑-4-基-甲酮衍生物以及包含其的pbk抑制剂 | |
| US8546368B2 (en) | Pyrazoloquinolones are potent PARP inhibitors | |
| CN101155797B (zh) | 在2-位上被一个季碳原子取代的1h-苯并咪唑-4-甲酰胺化合物是有效的parp抑制剂 | |
| JP5228237B2 (ja) | 置換１ｈ−ベンゾイミダゾール−４−カルボキサミドは強力なｐａｒｐ阻害薬である | |
| TWI748492B (zh) | 作為組蛋白去乙醯酶6抑制劑之1,3,4-㗁二唑衍生物及含彼之醫藥組合物 | |
| AU1345001A (en) | 2-benzyl and 2-heteroaryl benzimidazole nmda/nr2b antagonists | |
| TW200930370A (en) | Hedgehog pathway antagonists and therapeutic applications thereof | |
| JP2011529903A (ja) | ベンゾイミダゾール誘導体およびこれを含むグリコーゲンシンターゼキナーゼ３β阻害剤 | |
| MX2011013294A (es) | Antagonistas de la trayectoria de hedgehog y aplicaciones terapeuticas de los mismos. | |
| AU2006209712A1 (en) | IGF-1R inhibitor | |
| CN102292083A (zh) | 包括7-羟基-苯并咪唑-4-基-甲酮衍生物的糖原合酶激酶-3β抑制剂 | |
| US20080076813A1 (en) | Benzene, Pyridine, and Pyridazine Derivatives | |
| TW202329941A (zh) | Ｐａｄ４抑制劑及其用途 | |
| AU2006291414A1 (en) | Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | |
| WO2020147848A1 (zh) | 三环取代的氧杂螺环衍生物、其制法与医药上的用途 | |
| DE10006297A1 (de) | Substituierte Benzimidazole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C04 | Withdrawal of patent application after publication (patent law 2001) | ||
| WW01 | Invention patent application withdrawn after publication |
Open date: 20111221 |